<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750437</url>
  </required_header>
  <id_info>
    <org_study_id>YH1885L-201</org_study_id>
    <nct_id>NCT01750437</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)</brief_title>
  <official_title>Randomized, Double-blind, Active-controlled, Multi-center Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, active-controlled, multi-center phase 2 clinical trial to
      investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive
      reflux disease(NERD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of subject who had 'complete recovery' of symptom after 4 week administration</measure>
    <time_frame>4 week</time_frame>
    <description>'complete recovery' means subjects never experience heartburn or acid regurgitation during last 1 week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of subject who had 'appropriate recovery' of symptom after 4 week administration</measure>
    <time_frame>4 week</time_frame>
    <description>'Appropriate recovery' means subjects experience heartburn or acid regurgitation only 1 or less during last 1 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of subject who had 'complete recovery' after 1 week, 2 week, 3 week IP administraion</measure>
    <time_frame>3 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of subject who had 'appropriate recovery' after 1 week, 2 week, 3 week IP administraion</measure>
    <time_frame>3 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of night symptom-free day after IP administration</measure>
    <time_frame>1 week, 2 week, 3 week, 4 week</time_frame>
    <description>Symptoms means &quot;Heartburn or Acid regurgitation&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of subjects who have reduced average symptom score(more than 1) comparing to baseline score</measure>
    <time_frame>1 week, 2 week, 3 week, 4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evalution of Clinical Global Impression of Change</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Patient Global Impression of Change</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of SF-36 Survey score between baseline and completion visit</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of ESS survey score among baseline, 2 week and 4 week</measure>
    <time_frame>2, 4 week</time_frame>
    <description>ESS stands for Epworth sleepiness scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>4 week</time_frame>
    <description>AE, Physical exam, 12-lead ECG, Vital signs, laboratory test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of H.pylori(+),(-) subjects about primay and seconday outcome</measure>
    <time_frame>4 week</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>YH1885L 33.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TID, Subject takes it for 4 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1885L 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID, Subject takes it for 4 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1885L 66.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TID, Subject takes it for 4 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1885L 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID, Subject takes it for 4 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QD, Subject takes it for 4 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH1885L(Revaprazan)</intervention_name>
    <arm_group_label>YH1885L 33.3 mg</arm_group_label>
    <arm_group_label>YH1885L 50mg</arm_group_label>
    <arm_group_label>YH1885L 66.6 mg</arm_group_label>
    <arm_group_label>YH1885L 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 20mg</intervention_name>
    <arm_group_label>Esomeprazole 20mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>YH1885L 50mg</arm_group_label>
    <arm_group_label>YH1885L 100mg</arm_group_label>
    <arm_group_label>Esomeprazole 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects who signed written informed consent form

          -  more than 20 yr subject

          -  subjects who agree the use of medically accepted birth control during trial

          -  grade N, M by EGD test

          -  subject who experience 2 day out of 1 week during recent 1 month

          -  subject who experience 2 day out of 1 week during run-in period

        Exclusion Criteria:

          -  subjects who can write the diary by himself, herself

          -  pregnant woman, breastfeeding woman

          -  allgeric or intolerabiliy to revaprazan or esomeprazole

          -  feeling of heavy stomach, distention

          -  surgery history in stomach or esophagus

          -  active medical history of stomach, esophagus area

          -  other system disorder which can disturb this trial

          -  Hep B, C virus, HIV carrier or patients

          -  past history of malignant tumor

          -  any psychiatric past or current history

          -  abnormal lab test

          -  abnormal ecg test

          -  zollinger-ellison disease

          -  current or past history of substance, drug abuse

          -  subject who should regulary takes medication which can disturb this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DongA university hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungbook University hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam university hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic Incheon hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeonbuk University hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic yeouido sungmo hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk unversity hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

